Increased PARP activity and DNA damage in NSCLC patients: the influence of COPD

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Tang, Jun
• dc.contributor.author Curull Serrano, Víctor
• dc.contributor.author Wang, Xuejie
• dc.contributor.author Ampurdanés, Coral
• dc.contributor.author Duran Jordà, Xavier, 1974-
• dc.contributor.author Pijuan Andujar, Lara
• dc.contributor.author Rodríguez-Fuster, Alberto
• dc.contributor.author Aguiló Espases, Rafael
• dc.contributor.author Yélamos López, José
• dc.contributor.author Barreiro Portela, Esther
• dc.date.accessioned 2021-03-31T06:06:21Z
• dc.date.available 2021-03-31T06:06:21Z
• dc.date.issued 2020
• dc.description.abstract Background: Lung cancer (LC) is a major leading cause of death worldwide. Poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 are key players in cancer. We aimed to assess PARP-1 and PARP-2 expression and activity and DNA damage in tumors and non-tumor lungs from patients with/without chronic obstructive pulmonary disease (COPD). (2) Methods: Lung tumor and non-tumor specimens were obtained through video-assisted thoracoscopic surgery (VATS) in LC patients with/without underlying COPD (two groups of patients, n = 15/group). PARP-1 and PARP-2 expression (ELISA), PARP activity (PARP colorimetric assay kit) and DNA damage (immunohistochemistry) levels were identified in all samples. (3) Results: Both PARP-1 and PARP-2 expression levels were significantly lower in lung tumors (irrespective of COPD)compared to non-tumor specimens, while DNA damage and PARP activity levels significantly increased in lung tumors compared to non-tumor specimens only in LC-COPD patients. PARP-2 expression was positively correlated with smoking burden in LC-COPD patients. (4) Conclusions: In lung tumors of COPD patients, an overactivation of PARP enzyme was observed. A decline in PARP-1 and PARP-2 protein expression was seen in lung tumors irrespective of COPD. Other phenotypic features (airway obstruction) beyond cancer may account for the increase in PARP activity seen in the tumors of patients with underlying COPD.
• dc.format.mimetype application/pdf
• dc.identifier.citation Tang J, Curull V, Wang X, Ampurdanés C, Duran X, Pijuan L, Rodríguez-Fuster A, Aguiló R, Yélamos J, Barreiro E. Increased PARP activity and DNA damage in NSCLC patients: the influence of COPD. Cancers (Basel). 2020; 12(11):3333. DOI: 10.3390/cancers12113333
• dc.identifier.doi http://dx.doi.org/10.3390/cancers12113333
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/46997
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Cancers (Basel). 2020; 12(11):3333
• dc.rights © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword COPD
• dc.subject.keyword DNA damage
• dc.subject.keyword PARP activity
• dc.subject.keyword PARP-1 and PARP-2 expression
• dc.subject.keyword Lung cancer
• dc.title Increased PARP activity and DNA damage in NSCLC patients: the influence of COPD
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion